Fresenius Group, Davita Inc. and C. R. Bard, Inc. are Dominating the Market for Global Hemodialysis and Peritoneal Dialysis Market In 2017

Global Hemodialysis and Peritoneal Dialysis Market is expected to reach USD 115,783.6 million by 2025 from USD 68,922.9 million in 2017, at a CAGR of 6.8% in the forecast period 2018 to 2025. The new market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.Global Hemodialysis & Peritoneal Dialysis MarketAccess Full Report:

The global hemodialysis and peritoneal dialysis methods market is highly concentrated to a few big players and rest to local players who cater to domestic markets only. Fresenius Medical Care dominated the hemodialysis and peritoneal dialysis methods market accounting for a highest market share in 2017, followed by DaVita Inc. and C. R. Bard, Inc. Other players in this market include are Baxter, B. Braun Melsungen AG, Diaverum, Nipro, Nxstage Medical, Inc., Nikkiso Co., Ltd., Mar Cor Purification, Asahi Kasei Medical Co., Ltd, Rockwell Medical, Medtronic, Dialifegroup, JMS Co.Ltd., Atlantic Biomedical, 3M, Allmed Medical Care Holdings Limited., Isopure Corp. among others.


Fresenius group founded year is 1912, its headquateris located at  Bad Homburg, Germany. It is a global healthcare group company, it offers high-quality products and services for dialysis, hospitals, and outpatient treatment. It has 250,000 employees in 100 countries around the globe. Fresenius is one of the world’s leading healthcare companies.

The Fresenius Group has  four business segments which are IV Drugs, Clinical Nutrition, Infusion therapy and Medical device  , each one active in a major growth area of healthcare. Fresenius Medical Care is the world leader in treating people with chronic kidney failure. Fresenius Helios is Europe’s largest private hospital operator. Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services to help critically and chronically ill patients, while Fresenius Vamed plans, develops and manages healthcare facilities.

The company has several subsidiaries including Fresenius Kabi (Germany), Fresenius Proserve Gmbh, HELIOS Kliniken GmbH, Fresenius Kabi Australia Pty Limited (Australia), Fresenius Finance Ireland Public Limited Company (Ireland), Sino-Swed Pharmaceutical Corp. Ltd., Sino-Swed Pharmaceutical Corp. Ltd., Fresenius Kabi Anti-Infectives S.r.l., Else Kröner-Fresenius Foundation and FRESENIUS MANAGEMENT SERVICES, INC.

 Davita Inc.:

Davita Inc., founded in 1994 and is headquartered in Denver, U.S. The company provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). It operates through two divisions, DaVita Kidney Care and DaVita Medical Group. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services. It also owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients.

In addition, the company operates DaVita Rx, a pharmacy that provides oral medications to patients with ESRD; disease management services; vascular access services; clinical research programs; physician services; and direct primary care services.

The company has global presence in U.S., Brazil, China, Colombia, Germany, India, Malaysia, Netherlands, Poland, Portugal, Saudi Arabia and Taiwan, through its subsidiaries - DVA Renal Healthcare Inc (U.S.), Davita Medical Management, LLC (U.S.), Davita Rx (U.S.) Kidney Care Services, LLC (California U.S.), Total Renal Care, Inc (U.S.), HomeChoice Partners, Inc (U.S.), DVA Healthcare Renal Care, Inc (California, U.S.) and DVA Healthcare of Maryland Inc (U.S.)

R. Bard, Inc.:

Founded in 1907 and headquartered at Murray Hill, New Jersey, U.S. C. R. Bard, Inc. is one of the leading manufacturer and provider of medical technologies. The company operates in four business segments namely vascular, urology, oncology and surgical specialties. The vascular segment offers a wide range of products for endovascular and grafts includes biopsy devices, peripheral angioplasty catheters, drug-coated PTA balloons, vena cava filters, peripheral vascular stents and stent grafts, dialysis access grafts and peripheral vascular grafts. The urology segment of the company offers various products pertaining to basic drainage, continence, urological specialty, catheter stabilization, targeted temperature and management’s products.  The oncology segment of the company offers various devices including implantable ports, peripherally inserted central catheters (PICCs) and vascular access ultrasounds. The key products included in the surgical specialties are soft tissue repair, performance irrigation and bio-surgical products.

  • R. Bard, Inc. has companies operating across the North America, Europe, Middle East, and Asia-Pacific. Some of its subsidiaries include Bard Access System Inc. (U.S.), Bard Medical Division (U.S.), Davol Inc. (U.S.), Bard Peripheral Vascular, Inc. (U.S.), Bard Limited (U.K.), Bard Biopsy System (U.S.), Bard LAPAC (U.S.), Liberator Medical Supply, Inc. (U.S.), C. R. Bard GmbH (UAE) and many more subsidiaries across the globe.